At the conclusion of sessions yesterday, March 5, at the 2014 Conference on Retroviruses and Opportunistic Infections in Boston, NIH's Dr. Carl Dieffenbach sat down with Dr. Ron Valdiserri to discuss some of the day’s scientific highlights.
In their video conversation below, Dr. Dieffenbach observes that three significant advances in HIV therapies were among the day’s key highlights. These include a new agent that looks to be a promising future addition to the range of HIV treatments, new studies of several existing HIV drugs in new combinations that proved to be safer and better tolerated that will give patients new options. New research on long-acting therapies that could eventually simplify treatment—and, possibly, improve adherence—by replacing daily pill doses with a long-acting injectable drug formulation that requires injection only once a month or even less frequently.
View their conversation below:
Tomorrow is the last day of CROI. Dr. Dieffenbach will share with Dr. Valdiserri some of his overall observations on important findings shared at CROI 2014.